Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

Anthe S. Zandvliet, Jan H.M. Schellens, William Copalu, Jos H. Beijnen, Alwin D.R. Huitema

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

7 Citaten (Scopus)


Aim Chemotherapy with indisulam causes myelosuppression. This study aimed to evaluate the influence of patient-related covariates on pharmacokinetics and pharmacodynamics, to identify patients at risk for severe myelosuppression and to develop a dosing algorithm for treatment optimization. Methods Pharmacokinetic and pharmacodynamic data of 412 patients were available. Non-linear mixed effects modeling was used to determine the relative risk of dose-limiting myelosuppression for various covariates (demographics, physical condition, prior treatment, comedication, CYP2C genotype and biochemistry). Results Body surface area (BSA), race and CYP2C genotype had a significant impact on indisulam elimination (P < 0.001). Low BSA, Japanese race, variant CYP2C genotype, low baseline neutrophil and thrombocyte counts and female sex were clinically relevant risk factors of dose-limiting myelosuppression (RR > 1.1). A dosing strategy was developed to optimize treatment for patient subgroups. Conclusions This study has identified covariates related to an increased risk of myelosuppression after indisulam therapy. Dose individualization may contribute to treatment optimization.

Originele taal-2Engels
Pagina's (van-tot)39-62
Aantal pagina's24
TijdschriftJournal of Pharmacokinetics and Pharmacodynamics
Nummer van het tijdschrift1
StatusGepubliceerd - feb. 2009
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression'. Samen vormen ze een unieke vingerafdruk.

Citeer dit